Which brand name corresponds to the combination of Dextromethorphan and Bupropion?

The correct answer, Auvelity, reflects a medication that combines Dextromethorphan, which has been explored for its potential effects on depression, and Bupropion, an established antidepressant known for its unique mechanism of action. This combination is particularly relevant in treating major depressive disorder as the components may work synergistically to enhance therapeutic benefits.

Dextromethorphan acts on the sigma-1 receptors, which can have neuroprotective and antidepressant properties. Bupropion, on the other hand, primarily affects the neurotransmitters norepinephrine and dopamine, thereby targeting different pathways in the brain associated with mood regulation. The integration of these two substances in Auvelity is designed to potentially bolster the antidepressant effect while addressing various aspects of mood disorders.

This makes Auvelity a notable pharmacological development in the treatment landscape for depression, particularly for patients who may not respond adequately to traditional single-drug therapy.